Ariana is currently developing a set of software combined with laboratory tests that enable personalized treatment selection in oncology. Ariana has also developed algorithms that have been embedded in personalized medicine diagnostic tools. Ariana conducts these projects through partnerships with pharmaceutical and diagnostic companies as well as academic partners.
Ariana’s technology and expertise are also offered through consulting and data analysis services as well as licensing agreements for the KEM® software suite. Ariana’s team is multidisciplinary and highly experienced with degrees in Medicine, Computational Biology, Biostatistics, Biomathematics and Artificial Intelligence. Founded in 2003 as a spin-off of Institut Pasteur, Ariana is based in Paris and has a fully owned subsidiary in the U.S. It has entered into a distribution agreement with a Japanese provider, CT-LS.
Additionally, analyses performed by Ariana will offer a better understanding of the molecular mechanisms underlying the therapeutic compounds action and will facilitate an efficient and rapid development of new targeted therapies.